XML 29 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
Fair Value Measurements
12 Months Ended
Dec. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements

8. FAIR VALUE MEASUREMENTS

The carrying amounts of cash and cash equivalents, patient accounts receivable, accounts payable, accrued expenses and other current liabilities approximate their fair values due to the short-term maturities of the instruments.

The Company’s other assets and other liabilities measured at fair value are as follows (amounts in thousands):

 

 

Fair Value Measurements at December 30, 2023

 

 

Level 1

 

Level 2

 

Level 3

 

Total

 

Assets:

 

 

 

 

 

 

 

 

Interest rate cap agreements

$

-

 

$

30,455

 

$

-

 

$

30,455

 

Interest rate swap agreements

 

-

 

 

23,022

 

 

-

 

 

23,022

 

Total derivative assets

$

-

 

$

53,477

 

$

-

 

$

53,477

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements at December 31, 2022

 

 

Level 1

 

Level 2

 

Level 3

 

Total

 

Assets:

 

 

 

 

 

 

 

 

Interest rate cap agreements

$

-

 

$

47,459

 

$

-

 

$

47,459

 

Interest rate swap agreements

 

-

 

 

34,291

 

 

-

 

 

34,291

 

Total derivative assets

$

-

 

$

81,750

 

$

-

 

$

81,750

 

 

During the fiscal years ended December 30, 2023 and December 31, 2022, there were no transfers between Level 1, Level 2, and Level 3.

The fair values of the interest rate swap and cap agreements are based on the estimated net proceeds or costs to settle the transactions as of the respective balance sheet dates. The valuations are based on commercially reasonable industry and market practices for valuing similar financial instruments. See Note 9 – Derivative Financial Instruments for further details on the Company’s interest rate swap and cap agreements.

For the annual goodwill impairment test, the Company performs a Step 1 analysis that uses a combination of expected present value of future cash flows (income approach) and comparable public companies (market approach) to determine the fair value of the reporting unit. These approaches use primarily unobservable inputs, including revenue growth rates, projected EBITDA margins, and discount rates, which are considered Level 3 fair value measurements. The fair value analysis takes into account recent and expected operating performance.

See Note 11 – Share-Based Compensation for further details on the Company’s deferred restricted stock units.